☆ 4.6 Article

Mucosal Application of a Low-Energy Electron Inactivated Respiratory Syncytial Virus Vaccine Shows Protective Efficacy in an Animal Model

VIRUSES-BASEL (2023)

Related references

Note: Only part of the references are listed.

Review Infectious Diseases

Respiratory syncytial virus prevention within reach: the vaccine and monoclonal antibody landscape

Natalie Mazur et al.

Summary: Respiratory syncytial virus (RSV) is a major cause of infant mortality and morbidity in older adults. Efforts are being made to develop RSV vaccines and immunoprophylaxis using various approaches, with 33 candidates currently in clinical development. Understanding antibody targets has led to more rational and structure-based vaccine design. An extended half-life monoclonal antibody for infants is expected to receive regulatory approval within a year. Other approaches include live-attenuated vaccines for older infants, subunit vaccines for pregnant women, and vector and nucleic acid vaccines for older adults. Ensuring access and affordability of RSV vaccines globally is a priority.

LANCET INFECTIOUS DISEASES (2023)

Add to Collection

Article Pharmacology & Pharmacy

Identification and evaluation of a novel tribenzamide derivative as an inhibitor targeting the entry of the respiratory syncytial virus

Leila Issmail et al.

Summary: Human respiratory syncytial virus (RSV) is a major cause of severe lower respiratory tract infections, and there are currently no licensed vaccines or effective treatments available. A novel compound, 2f, has been identified as a potent inhibitor of RSV and shows promise for further development as an antiviral agent.

ANTIVIRAL RESEARCH (2023)

Add to Collection

News Item Multidisciplinary Sciences

'A good day': FDA approves world's first RSV vaccine

Myriam Vidal Valero

Summary: US regulatory agency approves GSK's vaccine, marking the end of a decades-long quest.

NATURE (2023)

Add to Collection

News Item Biochemistry & Molecular Biology

mRNA vaccine effective against RSV respiratory disease

Thiago Carvalho

Summary: This article summarizes the report from Nature Medicine on Moderna's clinical trial of a vaccine against respiratory syncytial virus in older adults.

NATURE MEDICINE (2023)

Add to Collection

Article Medicine, General & Internal

Efficacy and Safety of a Bivalent RSV Prefusion F Vaccine in Older Adults

E. E. Walsh et al.

Summary: The RSVpreF vaccine showed efficacy in preventing RSV-associated lower respiratory tract illness and RSV-associated acute respiratory illness in adults (>= 60 years of age), with no evident safety concerns.

NEW ENGLAND JOURNAL OF MEDICINE (2023)

Add to Collection

Article Medicine, General & Internal

Respiratory Syncytial Virus Prefusion F Protein Vaccine in Older Adults

Alberto Papi et al.

Summary: A phase 3 clinical trial showed that a candidate vaccine for respiratory syncytial virus (RSV) infection has a high efficacy in preventing RSV-related respiratory infection and lower respiratory tract disease in older adults. The vaccine was effective against both RSV subtypes and in individuals with underlying conditions.

NEW ENGLAND JOURNAL OF MEDICINE (2023)

Add to Collection

Article Parasitology

Apicomplexan parasites are attenuated by low-energy electron irradiation in an automated microfluidic system and protect against infection with Toxoplasma gondii

Julia Finkensieper et al.

Summary: Radiation-attenuated intracellular parasites are potential immunization strategies, and low-energy electron irradiation (LEEI) is evaluated as a method for generating replication-deficient Toxoplasma gondii and Cryptosporidium parvum. LEEI-treated parasites invade host cells but are unable to replicate, and antibody-based analysis shows no structural damage. Immunization of mice with LEEI-attenuated T. gondii induces high levels of antibodies and provides protection against acute infection, suggesting LEEI is a useful technology for developing anti-parasitic vaccines.

PARASITOLOGY RESEARCH (2023)

Add to Collection

Article Hematology

Vaccine-induced immune thrombotic thrombocytopenia

Frederikus A. Klok et al.

Summary: In response to the COVID-19 pandemic, vaccines for SARS-CoV-2 were rapidly developed and introduced, leading to a major impact on the evolution of the disease. However, reports of rare side-effects such as vaccine-induced immune thrombotic thrombocytopenia (VITT) have emerged, requiring prompt testing and treatment with intravenous immunoglobulin and non-heparin anticoagulants.

LANCET HAEMATOLOGY (2022)

Add to Collection

Review Allergy

The unfulfilled potential of mucosal immunization

James R. Baker et al.

Summary: Recent events have brought attention to vaccination strategies amidst the global coronavirus pandemic. Mucosal immunization, although lagging in implementation, offers several advantages such as localized infection protection and induction of long-term immunity. This review highlights the potential benefits of mucosal immunity, explores barriers to its implementation, examines immune mechanisms, and discusses recent developments in mucosal vaccination.

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2022)

Add to Collection

Article Medicine, General & Internal

Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in children younger than 5 years in 2019: a systematic analysis

You Li et al.

Summary: Respiratory syncytial virus (RSV) plays a significant role in morbidity and mortality burden globally in children aged 0-60 months, especially during the first 6 months of life and in low-income and middle-income countries. Passive immunization programs targeting RSV could have a substantial effect on reducing disease burden.

LANCET (2022)

Add to Collection

Article Medicine, General & Internal

Nirsevimab for Prevention of RSV in Healthy Late-Preterm and Term Infants

Laura L. Hammitt et al.

Summary: A single injection of nirsevimab administered before the RSV season protected healthy late-preterm and term infants from medically attended RSV-associated lower respiratory tract infection.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

Add to Collection

Article Immunology

Low-Energy Electron Irradiation of Tick-Borne Encephalitis Virus Provides a Protective Inactivated Vaccine

Julia Finkensieper et al.

Summary: Tick-borne encephalitis virus (TBEV) is a zoonotic flavivirus that can cause severe neurological complications in humans. Traditional methods of producing TBEV vaccines using formaldehyde have drawbacks, and this study suggests that low-energy electron irradiation (LEEI) could be an alternative method. Immunizing mice with LEEI-inactivated TBEV resulted in higher levels of antibodies and complete protection against viral challenge.

FRONTIERS IN IMMUNOLOGY (2022)

Add to Collection

Article Immunology

Investigations Into the Suitability of Bacterial Suspensions as Biological Indicators for Low-Energy Electron Irradiation

Simone Schopf et al.

Summary: Low-energy electron irradiation is an emerging alternative technology for pathogen inactivation in medical, biotechnological, and pharmaceutical applications. However, there is a lack of precise dose monitoring systems for low-energy irradiation processes in liquids or suspensions. In this study, three bacterial species were evaluated as biological dose indicators, and their inactivation kinetics and growth behavior were studied under low-energy accelerated electron irradiation.

FRONTIERS IN IMMUNOLOGY (2022)

Add to Collection

Review Immunology

An Overview of Vaccine Adjuvants: Current Evidence and Future Perspectives

Alessio Facciola et al.

Summary: Vaccines are crucial in preventing infectious diseases, and adjuvants play a key role in enhancing vaccine efficacy. Recent research has focused on developing new compounds with effective adjuvant properties and improved safety. Modern technologies like nanotechnologies and molecular biology have improved vaccine production by enhancing both antigen and adjuvant components. Microparticles, emulsions, and immune stimulators are being explored for their potential in vaccine production. While vaccine adjuvants may have potential side effects, the significant value of vaccines cannot be denied, particularly in managing future pandemics. Research into adjuvants could play a leading role in producing more effective vaccines.

VACCINES (2022)

Add to Collection

Article Immunology

Mucosal immunization with an adenoviral vector vaccine confers superior protection against RSV compared to natural immunity

Clara Maier et al.

Summary: RSV infections are a major cause of severe respiratory illness in infants. Immune responses at respiratory mucosae play an important role in effective immunity. A mucosal vaccine based on RSV fusion protein and genetic adjuvants IL-1 beta and IPS-1 showed promising results in controlling RSV infection.

FRONTIERS IN IMMUNOLOGY (2022)

Add to Collection

Article Immunology

A Recombinant MVA-Based RSV Vaccine Induces T-Cell and Antibody Responses That Cooperate in the Protection Against RSV Infection

Kathrin Endt et al.

Summary: Respiratory syncytial virus (RSV) is a respiratory disease that poses a potential fatality risk to infants and elderly individuals. Despite previous failed attempts, researchers have developed an RSV vaccine using recombinant Modified Vaccinia Virus Ankara-BN (MVA-RSV), which has shown promising results in clinical trials. This study demonstrates that the MVA-RSV vaccine provides optimal protection against RSV infection by activating multiple components of the adaptive immune system, including CD4 and CD8 T cells and antibodies such as IgA.

FRONTIERS IN IMMUNOLOGY (2022)

Add to Collection

Review Immunology

Mucosal vaccines - fortifying the frontiers

Ed C. Lavelle et al.

Summary: Mucosal vaccines have the potential to prevent infections and protect against disease development by inducing adaptive immunity at mucosal sites. However, most current mucosal vaccines consist of live attenuated and inactivated whole-cell preparations, and there is a need for safe and effective mucosal adjuvants and innovative antigen discovery and delivery strategies to advance these vaccines. Advancements in understanding innate and adaptive mucosal immunity, including mucosal antigen-presenting cells and resident memory cells, provide valuable insights to inform mucosal adjuvant design for pathogens like SARS-CoV-2 and cancer.

NATURE REVIEWS IMMUNOLOGY (2022)

Add to Collection

Article Immunology

Immune thrombocytopenia following immunisation with Vaxzevria ChadOx1-S (AstraZeneca) vaccine, Victoria, Australia

Sally F. Gordon et al.

Summary: The study found a significantly higher incidence of ITP following AstraZeneca vaccination than expected, while the incidence following Pfizer-BioNTech vaccination was consistent with expectations. Most cases required hospitalization or medical treatment, with 11 cases needing intervention with multiple therapy modalities.

VACCINE (2021)

Add to Collection

Article Multidisciplinary Sciences

Protective mucosal immunity against SARS-CoV-2 after heterologous systemic prime-mucosal boost immunization

Dennis Lapuente et al.

Summary: The study demonstrates that priming with systemic mRNA and boosting with intranasal adenoviral vector vaccine in mice induces comprehensive T cell and mucosal immunity. The strategy provides complete protection against SARS-CoV-2 infection in mice after boosting.

NATURE COMMUNICATIONS (2021)

Add to Collection

Article Immunology

Prefusion F-Based Polyanhydride Nanovaccine Induces Both Humoral and Cell-Mediated Immunity Resulting in Long-Lasting Protection against Respiratory Syncytial Virus

Laura M. Stephens et al.

Summary: The novel RSV vaccine RSVNanoVax showed protective effects against RSV infection in experiments, reducing weight loss and pulmonary dysfunction, with protection lasting at least 6 months. Additionally, the vaccine was able to rapidly clear RSV from the lungs, induce tissue-resident memory T cells, and produce neutralizing antibodies against RSV.

JOURNAL OF IMMUNOLOGY (2021)

Add to Collection

Article Virology

Dynamic Host Immune and Transcriptomic Responses to Respiratory Syncytial Virus Infection in a Vaccination-Challenge Mouse Model

Yu Zhao et al.

Summary: UV-RSV vaccination induces a Th2 type inflammatory response in the lungs, characterized by enhanced histopathology, reduced Treg cells, and increased IL4(+)CD4 T cells. Additionally, UV-RSV vaccination leads to increased production of several Th2 type cytokines and decreases in IL-6 and IL-17.

VIROLOGICA SINICA (2021)

Add to Collection

Article Respiratory System

TMEM16A/ANO1 calcium-activated chloride channel as a novel target for the treatment of human respiratory syncytial virus infection

Hayley Pearson et al.

Summary: HRSV is a common cause of respiratory infections globally, particularly fatal for infants. Research has identified the TMEM16A channel as crucial for HRSV infection, suggesting it as a potential target for future antiviral therapies.

THORAX (2021)

Add to Collection

Review Immunology

Adenovirus Vectors: Excellent Tools for Vaccine Development

Jun Chang

Summary: Adenovirus, originally used for gene therapy, has seen increased utility as a vaccine vector in recent years with higher safety and immunogenicity. It is being tested for preventing infectious diseases and as cancer vaccines, with ongoing research to overcome limitations for improved vaccine development using adenovirus vectors.

IMMUNE NETWORK (2021)

Add to Collection

Editorial Material Pharmacology & Pharmacy

Non-invasive mucosal vaccine delivery: advantages, challenges and the future

Mariusz Skwarczynski et al.

EXPERT OPINION ON DRUG DELIVERY (2020)

Add to Collection

Review Biotechnology & Applied Microbiology

Immune Responses to Viral Gene Therapy Vectors

Jamie L. Shirley et al.

MOLECULAR THERAPY (2020)

Add to Collection

Article Multidisciplinary Sciences

Automated application of low energy electron irradiation enables inactivation of pathogen- and cell-containing liquids in biomedical research and production facilities

Jasmin Fertey et al.

SCIENTIFIC REPORTS (2020)

Add to Collection

Review Immunology

Mucosal vaccines and technology

A. Miquel-Clopes et al.

CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2019)

Add to Collection

Article Immunology

2777. Live-Attenuated Vaccine Against RSV Generates Robust Cellular and Humoral Immune Responses

Steffen Mueller et al.

Open Forum Infectious Diseases (2019)

Add to Collection

Article Immunology

Severe Morbidity and Mortality Associated With Respiratory Syncytial Virus Versus Influenza Infection in Hospitalized Older Adults

Bradley Ackerson et al.

CLINICAL INFECTIOUS DISEASES (2019)

Add to Collection

Article Chemistry, Physical

Low-energy electron-beam treatment as alternative for on-site sterilization of highly functionalized medical products - A feasibility study

G. Gotzmann et al.

RADIATION PHYSICS AND CHEMISTRY (2018)

Add to Collection

Article Immunology

Immunization with an adjuvanted low-energy electron irradiation inactivated respiratory syncytial virus vaccine shows immunoprotective activity in mice

Lea Bayer et al.

VACCINE (2018)

Add to Collection

Article Public, Environmental & Occupational Health

Update on Vaccine-Derived Polioviruses - Worldwide, January 2017-June 2018

Jaume Jorba et al.

MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT (2018)

Add to Collection

Article Biotechnology & Applied Microbiology

ICTV Virus Taxonomy Profile: Pneumoviridae

Bert Rima et al.

JOURNAL OF GENERAL VIROLOGY (2017)

Add to Collection

Article Immunology

Effectiveness of Palivizumab in High-risk Infants and Children A Propensity Score Weighted Regression Analysis

Evan J. Anderson et al.

PEDIATRIC INFECTIOUS DISEASE JOURNAL (2017)

Add to Collection

Review Immunology

The development of mucosal vaccines for both mucosal and systemic immune induction and the roles played by adjuvants

Sae-Hae Kim et al.

CLINICAL AND EXPERIMENTAL VACCINE RESEARCH (2017)

Add to Collection

Review Critical Care Medicine

Human Respiratory Syncytial Virus: Infection and Pathology

Karen Bohmwald et al.

SEMINARS IN RESPIRATORY AND CRITICAL CARE MEDICINE (2016)

Add to Collection

Article Toxicology

Prevalidation of the ex-vivo model PCLS for prediction of respiratory toxicity

A. Hess et al.

TOXICOLOGY IN VITRO (2016)

Add to Collection

Article Immunology

WHO consultation on Respiratory Syncytial Virus Vaccine Development Report from a World Health Organization Meeting held on 23-24 March 2015

Kayvon Modjarrad et al.

VACCINE (2016)

Add to Collection

Article Virology

Pathogens Inactivated by Low-Energy-Electron Irradiation Maintain Antigenic Properties and Induce Protective Immune Responses

Jasmin Fertey et al.

VIRUSES-BASEL (2016)

Add to Collection

Article Multidisciplinary Sciences

Pre-fusion F is absent on the surface of formalin-inactivated respiratory syncytial virus

April M. Killikelly et al.

SCIENTIFIC REPORTS (2016)

Add to Collection

Article Medicine, Research & Experimental

Mucosal delivery of a vectored RSV vaccine is safe and elicits protective immunity in rodents and nonhuman primates

Angiolo Pierantoni et al.

MOLECULAR THERAPY-METHODS & CLINICAL DEVELOPMENT (2015)

Add to Collection

Review Immunology

Recent Advances of Vaccine Adjuvants for Infectious Diseases

Sujin Lee et al.

IMMUNE NETWORK (2015)

Add to Collection

Review Immunology

Application of radiation technology in vaccines development

Ho Seong Seo

CLINICAL AND EXPERIMENTAL VACCINE RESEARCH (2015)

Add to Collection

Article Virology

Novel Vaccine Regimen Elicits Strong Airway Immune Responses and Control of Respiratory Syncytial Virus in Nonhuman Primates

Thomas Grunwald et al.

JOURNAL OF VIROLOGY (2014)

Add to Collection

Article Toxicology

Assessment of immunotoxicity induced by chemicals in human precision-cut lung slices (PCLS)

L. Lauenstein et al.

TOXICOLOGY IN VITRO (2014)

Add to Collection

Article Biochemistry & Molecular Biology

Phosphatidylglycerol provides short-term prophylaxis against respiratory syncytial virus infection

Mari Numata et al.

JOURNAL OF LIPID RESEARCH (2013)

Add to Collection

Article Virology

Protective and dysregulated T cell immunity in RSV infection

Peter J. Openshaw et al.

CURRENT OPINION IN VIROLOGY (2013)

Add to Collection

Review Cell Biology

Return of inactivated whole-virus vaccine for superior efficacy

Yoichi Furuya

IMMUNOLOGY AND CELL BIOLOGY (2012)

Add to Collection

Review Immunology

Design considerations for liposomal vaccines: Influence of formulation parameters on antibody and cell-mediated immune responses to liposome associated antigens

Douglas S. Watson et al.

VACCINE (2012)

Add to Collection

Review Immunology

Recent progress in mucosal vaccine development: potential and limitations

Nils Lycke

NATURE REVIEWS IMMUNOLOGY (2012)

Add to Collection

Article Genetics & Heredity

Adenoviral Vector Immunity: Its Implications and Circumvention Strategies

Yadvinder S. Ahi et al.

CURRENT GENE THERAPY (2011)

Add to Collection

Article Multidisciplinary Sciences

Pulmonary surfactant phosphatidylglycerol inhibits respiratory syncytial virus-induced inflammation and infection

Mari Numata et al.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)

Add to Collection

Article Materials Science, Coatings & Films

Surface modification of polyurethane and silicone for therapeutic medical technics by means of electron beam

C. Wetzel et al.

SURFACE & COATINGS TECHNOLOGY (2010)

Add to Collection

Article Virology

Protective Efficacy and Immunogenicity of an Adenoviral Vector Vaccine Encoding the Codon-Optimized F Protein of Respiratory Syncytial Virus

Rebekka Kohlmann et al.

JOURNAL OF VIROLOGY (2009)

Add to Collection

Article Medicine, General & Internal

Comparative Efficacy of Inactivated and Live Attenuated Influenza Vaccines

Arnold S. Monto et al.

NEW ENGLAND JOURNAL OF MEDICINE (2009)

Add to Collection

Article Veterinary Sciences

Assessing the functionality of viral entry-associated domains of porcine reproductive and respiratory syndrome virus during inactivation procedures, a potential tool to optimize inactivated vaccines

Iris Delrue et al.

VETERINARY RESEARCH (2009)

Add to Collection

Review Pharmacology & Pharmacy

Vaccine adjuvant systems: Enhancing the efficacy of sub-unit protein antigens

Yvonne Perrie et al.

INTERNATIONAL JOURNAL OF PHARMACEUTICS (2008)

Add to Collection

Article Multidisciplinary Sciences

Respiratory syncytial virus uses a Vps4-independent budding mechanism controlled by Rab11-FIP2

Thomas J. Utley et al.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)

Add to Collection

Article Immunology

Immunogenicity and efficacy of codon optimized DNA vaccines encoding the F-protein of respiratory syncytial virus

Nicola Ternette et al.

VACCINE (2007)

Add to Collection

Article Immunology

Understanding respiratory syncytial virus (RSV) vaccine-enhanced disease

Elaine M. Castilow et al.

IMMUNOLOGIC RESEARCH (2007)

Add to Collection

Article Biochemistry & Molecular Biology

A potential molecular mechanism for hypersensitivity caused by formalin- inactivated vaccines

Amin Moghaddam et al.

NATURE MEDICINE (2006)

Add to Collection

Review Immunology

Mucosal vaccines: the promise and the challenge

MR Neutra et al.

NATURE REVIEWS IMMUNOLOGY (2006)

Add to Collection

Article Medicine, General & Internal

Respiratory syncytial virus infection in elderly and high-risk adults

AR Falsey et al.

NEW ENGLAND JOURNAL OF MEDICINE (2005)

Add to Collection

Article Immunology

Identification of a recombinant live attenuated respiratory syncytial virus vaccine candidate that is highly attenuated in infants

RA Karron et al.

JOURNAL OF INFECTIOUS DISEASES (2005)

Add to Collection

Review Biotechnology & Applied Microbiology

Recent advances with liposomes as pharmaceutical carriers

VP Torchilin

NATURE REVIEWS DRUG DISCOVERY (2005)

Add to Collection

Article Medicine, General & Internal

Use of the inactivated intranasal influenza vaccine and the risk of Bell's palsy in Switzerland

M Mutsch et al.

NEW ENGLAND JOURNAL OF MEDICINE (2004)

Add to Collection

Article Virology

Enhanced mucosal immunoglobulin A response of intranasal adenoviral vector human immunodeficiency virus vaccine and localization in the central nervous system

F Lemiale et al.

JOURNAL OF VIROLOGY (2003)

Add to Collection

Article Immunology

The efficacy, effectiveness and cost-effectiveness of inactivated influenza virus vaccines

KL Nichol

VACCINE (2003)

Add to Collection

Article Immunology

A role for immune complexes in enhanced respiratory syncytial virus disease

FP Polack et al.

JOURNAL OF EXPERIMENTAL MEDICINE (2002)

Add to Collection

Article Immunology

Immunopathogenesis of vaccine-enhanced RSV disease

PJM Openshaw et al.

VACCINE (2001)

Add to Collection

© Peeref 2019-2024. All rights reserved.